Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma

✍ Scribed by Yoshihiko Maehara; Yoshihiro Kakeji; Akihiro Watanabe; Hideo Baba; Hiroki Kusumoto; Shunji Kohnoe; Keizo Sugimachi

• Publisher: John Wiley and Sons
• Year: 1999
• Tongue: English
• Weight: 256 KB
• Volume: 85
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/(sici)1097-0142(19990115)85:2<302::aid-cncr6>3.0.co;2-6

✦ Synopsis

Background:

Mutations of p53 can lead to the production of anti-p53 antibodies in sera of cancer patients. before this study, the value of preoperative serum anti-p53 antibodies in determining the prognoses of patients with gastric carcinoma had yet to be determined.

Methods:

The authors used a highly specific enzyme-linked immunosorbent assay (elisa) kit (pharma cell, france) to determine the preoperative presence of serum anti-p53 antibodies in 120 patients with gastric carcinoma. the relation between the positivity of serum anti-p53 antibodies and p53 abnormal staining of gastric carcinoma tissues was examined. clinicopathologic characteristics and prognoses of these patients were given attention.

Results:

Anti-p53 antibodies were detected in 19.2%(23 of 120) of these patients with gastric carcinoma. among those who were positive for anti-p53 antibodies, female patients were predominant, the depth of invasion was greater, and liver metastasis was present, as compared with those who were negative for anti-p53 antibodies. regarding other factors, there were no differences between those who were positive or negative for anti-p53 antibodies. gastric carcinoma tissues had a 60.9% (14 of 23) positivity rate of p53 staining with anti-p53 antibodies and a 33.0% (32 of 97) negativity rate, and this difference was statistically significant (p < 0.05). the survival time of patients with anti-p53 antibodies in their sera was shorter than that of subjects with sera negative for anti-p53 antibodies (p < 0.05). the presence of anti-p53 antibodies was not an independent prognostic factor in multivariate analysis.

Conclusions:

Serum assay of anti-p53 antibodies is a rapid and readily facilitated test for predicting tumor advancement, depth of invasion, and liver metastasis, and it will show a poorer prognosis for surgically treated patients with gastric carcinoma.